Cardiotoxic safety communications after FDA approval of novel cancer therapies.
Bonsu J, Kola-Kehinde O, Kim L, Ruz P, Lustberg M, Brammer J, Addison D. Cardiotoxic safety communications after FDA approval of novel cancer therapies. Journal Of Clinical Oncology 2021, 39: e18629-e18629. DOI: 10.1200/jco.2021.39.15_suppl.e18629.Peer-Reviewed Original ResearchBlack box warningNovel anticancer therapiesHeart failureNovel cancer therapiesThromboembolic diseaseBox warningCancer therapyCardiovascular disease eventsAnticancer therapyMultivariable logistic regressionSudden cardiac deathApproval statusNew safety informationPriority review statusUncontrolled hypertensionCVD eventsCardiac deathCoronary diseaseCVD deathDrug withdrawalElectrocardiographic changesMyocardial infarctionDrug classesLabel warningsMultivariable model